Lipit Sallarının Monoaminerjik Nörotransmiter Sistemlerinin Düzenlenmesindeki Rolü
Özet
Lipit salları, hücre membranının kolesterol ve sfingolipitlerden zengin, dinamik ve nano ölçekli bölgeleri olup monoaminerjik nörotransmisyonun düzenlenmesinde kritik bir rol oynamaktadır. Bu mikro-alanlar, majör depresif bozukluk gibi nöropsikiyatrik durumlarla ilişkili olan serotonin (SERT), dopamin (DAT) ve norepinefrin (NET) taşıyıcı proteinleri ile bunların reseptörlerinin sinyalizasyon süreçlerini regüle eder. Çalışmalar, SERT ve NET’in fonksiyonlarının ve hücre içine alınma süreçlerinin lipit sallarıyla doğrudan ilişkili olduğunu, kolesterol deplesyonunun bu taşıyıcıların aktivitesini önemli ölçüde azalttığını göstermektedir. DAT’ın durumu ise daha karmaşık olup, kolesterolden etkilense de bu etkilerin büyük oranda sal bölgelerinden bağımsız olduğu bildirilmiştir. Reseptör düzeyinde ise 5-HT1A, 5-HT2A ve 5-HT7 gibi serotonin reseptörlerinin lipit salları içinde kaveolinlerle birlikte lokalize olduğu ve bu alanların bütünlüğünün bozulmasının agonist bağlanmasını ve sinyal iletimini zayıflattığı tespit edilmiştir. Benzer şekilde, D1 ve β2-adrenerjik reseptörlerin de bu mikro-alanlarda sinyal bileşenleriyle etkileşime girdiği görülmüştür. Antidepresanların, Gαs proteinini lipit sallardan sal olmayan alanlara kaydırarak cAMP yolaklarını aktive ettiği ve bu mekanizmanın terapötik etkide rol oynadığı düşünülmektedir. Sonuç olarak, lipit sallarının farmakoterapötik bir hedef olarak potansiyeli yüksektir; ancak bu karmaşık etkileşimlerin tam olarak aydınlatılması için daha fazla klinik çalışmaya ihtiyaç duyulmaktadır.
Lipid rafts are dynamic, nano-scale regions of the cell membrane rich in cholesterol and sphingolipids, playing a critical role in regulating monoaminergic neurotransmission. These microdomains regulate the signaling processes of serotonin (SERT), dopamine (DAT), and norepinephrine (NET) transporter proteins, as well as their receptors, which are associated with neuropsychiatric conditions such as major depressive disorder. Studies indicate that the functions and internalization processes of SERT and NET are directly linked to lipid rafts, and cholesterol depletion significantly reduces the activity of these transporters. The case for DAT is more complex; while it is affected by cholesterol, these effects are reported to be largely independent of raft regions. At the receptor level, serotonin receptors such as 5-HT1A, 5-HT2A, and 5-HT7 are localized within lipid rafts alongside caveolins, and disrupting the integrity of these areas weakens agonist binding and signaling. Similarly, D1 and β2-adrenergic receptors have been observed to interact with signaling components in these microdomains. It is thought that antidepressants facilitate the translocation of Gαs protein from lipid rafts to non-raft areas, activating cAMP pathways and playing a role in their therapeutic effect. Consequently, the potential of lipid rafts as a pharmacotherapeutic target is high; however, more clinical studies are needed to fully elucidate these complex interactions.
Referanslar
Liu JJ, Hezghia A, Shaikh SR, et al. Regulation of monoamine transporters and receptors by lipit microdomains: implications for depression. Neuropsychopharmacology. 2018;43:2165-2179.
Lorent JH, Levental I. Structural determinants of protein partitioning into ordered membrane domains and lipit rafts. Chem Phys Lipits. 2015;192:23-32.
Levental I, Veatch S. The Continuing Mystery of Lipit Rafts. J Mol Biol. 2016;428:4749-4764.
Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipit raft microdomains and neurotransmitter signalling. Nat Rev Neurosci. 2007;8:128-140.
Hancock JF. Lipit rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol. 2006;7:456-462.
Head BP, Patel HH, Insel PA. Interaction of membrane/lipit rafts with the cytoskeleton: impact on signaling and function: membrane/lipit rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta. 2014;1838:532-545.
Trushina E, Du Charme J, Parisi J, McMurray CT. Neurological abnormalities in caveolin-1 knock out mice. Behav Brain Res. 2006;172:24-32.
Kovtun O, Tillu VA, Ariotti N, Parton RG, Collins BM. Cavin family proteins and the assembly of caveolae. J Cell Sci. 2015;128:1269-1278.
Nichols B. Caveosomes and endocytosis of lipit rafts. J Cell Sci. 2003;116:4707-4714.
Rajendran L, Simons K. Lipit rafts and membrane dynamics. J Cell Sci. 2005;118:1099-1102.
Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6:112-126.
Magnani F, Tate CG, Wynne S, et al. Partitioning of the serotonin transporter into lipit microdomains modulates transport of serotonin. J Biol Chem. 2004;279:38770-38778.
Scanlon SM, Williams DC, Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry. 2001;40:10507-10513.
Butler B, Saha K, Rana T, et al. Dopamine Transporter Activity Is Modulated by α-Synuclein. J Biol Chem. 2015;290:29542-29554.
Arapulisamy O, Mannangatti P, Jayanthi LD. Regulated norepinephrine transporter interaction with the neurokinin-1 receptor establishes transporter subcellular localization. J Biol Chem. 2013;288:28599-28610.
Triantafilou M, Morath S, Mackie A, Hartung T, Triantafilou K. Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipit rafts on the plasma membrane. J Cell Sci. 2004;117:4007-4014.
Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond B Biol Sci. 2013;368(1615):20120537. doi:10.1098/rstb.2012.0537
Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994;40:288-295.
Sellers EM, Higgins GA, Tompkins DM, Romach MK. Serotonin and alcohol drinking. NIDA Res Monogr. 1992;119:141-145.
Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl. 1989;8:52-62.
Compagnon P, Ernouf D, Narcisse G, Daoust M. Serotonin in animal models of alcoholism. Alcohol Alcohol Suppl. 1993;2:215-219.
Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990;51:14-20.
Gray NA, Milak MS, DeLorenzo C, et al. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry. 2013;74:26-31.
Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64:5-12.
Jayanthi LD, Vargas G, DeFelice LJ. Characterization of cocaine and antidepressant-sensitive norepinephrine transporters in rat placental trophoblasts. Br J Pharmacol. 2002;135:1927-1934.
Ramamoorthy S, Shippenberg TS, Jayanthi LD. Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol Ther. 2011;129:220-238.
Li Q, Ma L, Innis RB, et al. Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]-5-fluoromethylphenylamine (AFM) and 3-amino-4-[2-(dimethylaminomethyl-phenylthio)]benzonitrile (DASB). J Pharmacol Exp Ther. 2004;308:481-486.
Bengel D, Murphy DL, Andrews AM, et al. Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in serotonin transporter-deficient mice. Mol Pharmacol. 1998;53:649-655.
Rioux A, Fabre V, Lesch KP, et al. Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett. 1999;262:113-116.
Sora I, Hall FS, Andrews AM, et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc Natl Acad Sci U S A. 2001;98:5300-5305.
Adriani W, Boyer F, Gioiosa L, Macrì S, Dreyer J-L, Laviola G. Increased impulsive behavior and risk proneness following lentivirus-mediated dopamine transporter over-expression in rats’ nucleus accumbens. Neuroscience. 2009;159:47-58.
Gainetdinov RR, Caron MG. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol. 2003;43:261-284.
Gainetdinov RR, Wetsel WC, Jones SR, et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397-401.
Hall FS, Li XF, Sora I, et al. Cocaine mechanisms: enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience. 2002;115:153-161.
Torres GE, Carneiro A, Seamans K, et al. Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem. 2003;278:2731-2739.
Kocabas AM, Rudnick G, Kilic F. Functional consequences of homo- but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters. J Neurochem. 2003;85:1513-1520.
Anderluh A, Hofmaier T, Klotzsch E, et al. Direct PIP2 binding mediates stable oligomer formation of the serotonin transporter. Nat Commun. 2017;8:14089.
Liu Y, Casey L, Pike LJ. Compartmentalization of phosphatidylinositol 4,5-bisphosphate in low-density membrane domains in the absence of caveolin. Biochem Biophys Res Commun. 1998;245:684-690.
Pike LJ, Casey L. Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains. J Biol Chem. 1996;271:26453-26456.
Khelashvili G, Weinstein H. Functional mechanisms of neurotransmitter transporters regulated by lipit-protein interactions of their terminal loops. Biochim Biophys Acta. 2015;1848:1765-1774.
Buchmayer F, Schicker K, Steinkellner T, et al. Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proc Natl Acad Sci U S A. 2013;110:11642-11647.
Hamilton PJ, Belovich AN, Khelashvili G, et al. PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat Chem Biol. 2014;10:582-589.
Chang JC, Tomlinson ID, Warnement MR, et al. Single molecule analysis of serotonin transporter regulation using antagonist-conjugated quantum dots reveals restricted, p38 MAPK-dependent mobilization underlying uptake activation. J Neurosci. 2012;32:8919-8929.
Samuvel DJ, Jayanthi LD, Bhat NR, Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J Neurosci. 2005;25:29-41.
Foster JD, Adkins SD, Lever JR, Vaughan RA. Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem. 2008;105:1683-1699.
Jones KT, Zhen J, Reith MEA. Importance of cholesterol in dopamine transporter function. J Neurochem. 2012;123:700-715.
Adkins EM, Samuvel DJ, Fog JU, et al. Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry. 2007;46:10484-10497.
Sorkina T, Hoover BR, Zahniser NR, Sorkin A. Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic. 2005;6:157-170.
Vainio S, Jansen M, Koivusalo M, et al. Significance of sterol structural specificity. Desmosterol cannot replace cholesterol in lipit rafts. J Biol Chem. 2006;281:348-355.
Daniels GM, Amara SG. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem. 1999;274:35794-35801.
Saunders C, Ferrer J V, Shi L, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A. 2000;97:6850-6855.
Sorkina T, Caltagarone J, Sorkin A. Flotillins regulate membrane mobility of the dopamine transporter but are not required for its protein kinase C dependent endocytosis. Traffic. 2013;14:709-724.
Hong WC, Amara SG. Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem. 2010;285:32616-32626.
Jayanthi LD, Samuvel DJ, Ramamoorthy S. Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipit rafts and lipit raft-mediated internalization. J Biol Chem. 2004;279:19315-19326.
Mandela P, Ordway GA. The norepinephrine transporter and its regulation. J Neurochem. 2006;97:310-333.
Zhu MY, Ordway GA. Down-regulation of norepinephrine transporters on PC12 cells by transporter inhibitors. J Neurochem. 1997;68:134-141.
Fantini J, Barrantes FJ. Sphingolipit/cholesterol regulation of neurotransmitter receptor conformation and function. Biochim Biophys Acta. 2009;1788:2345-2361.
Kalipatnapu S, Chattopadhyay A. Membrane organization of the human serotonin(1A) receptor monitored by detergent insolubility using GFP fluorescence. Mol Membr Biol. 2005;22:539-547.
Renner U, Glebov K, Lang T, et al. Localization of the mouse 5-hydroxytryptamine(1A) receptor in lipit microdomains depends on its palmitoylation and is involved in receptor-mediated signaling. Mol Pharmacol. 2007;72:502-513.
Pucadyil TJ, Chattopadhyay A. Cholesterol modulates ligand binding and G-protein coupling to serotonin(1A) receptors from bovine hippocampus. Biochim Biophys Acta. 2004;1663:188-200.
Sjögren B, Csöregh L, Svenningsson P. Cholesterol reduction attenuates 5-HT1A receptor-mediated signaling in human primary neuronal cultures. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:441-446.
Jafurulla M, Tiwari S, Chattopadhyay A. Identification of cholesterol recognition amino acid consensus (CRAC) motif in G-protein coupled receptors. Biochem Biophys Res Commun. 2011;404:569-573.
Gutierrez MG, Mansfield KS, Malmstadt N. The Functional Activity of the Human Serotonin 5-HT1A Receptor Is Controlled by Lipit Bilayer Composition. Biophys J. 2016;110:2486-2495.
Mialet-Perez J, D’Angelo R, Villeneuve C, et al. Serotonin 5-HT2A receptor-mediated hypertrophy is negatively regulated by caveolin-3 in cardiomyoblasts and neonatal cardiomyocytes. J Mol Cell Cardiol. 2012;52:502-510.
Wu Z, Cheng H, Jiang Y, Melcher K, Xu HE. Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery. Acta Pharmacol Sin. 2015;36:895-907.
Nothdurfter C, Tanasic S, Di Benedetto B, et al. Impact of lipit raft integrity on 5-HT3 receptor function and its modulation by antidepressants. Neuropsychopharmacology. 2010;35:1510-1519.
Eisensamer B, Uhr M, Meyr S, et al. Antidepressants and antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J Neurosci. 2005;25:10198-10206.
Sjögren B, Svenningsson P. Depletion of the lipit raft constituents, sphingomyelin and ganglioside, decreases serotonin binding at human 5-HT7(a) receptors in HeLa cells. Acta Physiol (Oxf). 2007;190:47-53.
Sjögren B, Hamblin MW, Svenningsson P. Cholesterol depletion reduces serotonin binding and signaling via human 5-HT(7(a)) receptors. Eur J Pharmacol. 2006;552:1-10.
Beaulieu J-M, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015;172:1-23.
Obadiah J, Avidor-Reiss T, Fishburn CS, et al. Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs. Cell Mol Neurobiol. 1999;19:653-664.
Ilani T, Fishburn CS, Levavi-Sivan B, Carmon S, Raveh L, Fuchs S. Coupling of dopamine receptors to G proteins: studies with chimeric D2/D3 dopamine receptors. Cell Mol Neurobiol. 2002;22:47-56.
Jaber M, Robinson SW, Missale C, Caron MG. Dopamine receptors and brain function. Neuropharmacology. 1996;35:1503-1519.
Mystek P, Dutka P, Tworzydło M, Dziedzicka-Wasylewska M, Polit A. The role of cholesterol and sphingolipits in the dopamine D1 receptor and G protein distribution in the plasma membrane. Biochim Biophys Acta. 2016;1861:1775-1786.
Yu P, Sun M, Villar VAM, et al. Differential dopamine receptor subtype regulation of adenylyl cyclases in lipit rafts in human embryonic kidney and renal proximal tubule cells. Cell Signal. 2014;26:2521-2529.
Vickery RG, von Zastrow M. Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol. 1999;144:31-43.
Kong MMC, Hasbi A, Mattocks M, Fan T, O’Dowd BF, George SR. Regulation of D1 dopamine receptor trafficking and signaling by caveolin-1. Mol Pharmacol. 2007;72:1157-1170.
Voulalas PJ, Schetz J, Undieh AS. Differential subcellular distribution of rat brain dopamine receptors and subtype-specific redistribution induced by cocaine. Mol Cell Neurosci. 2011;46:645-654.
Paspalas CD, Goldman-Rakic PS. Microdomains for dopamine volume neurotransmission in primate prefrontal cortex. J Neurosci. 2004;24:5292-5300.
Sharma M, Celver J, Octeau JC, Kovoor A. Plasma membrane compartmentalization of D2 dopamine receptors. J Biol Chem. 2013;288:12554-12568.
Celver J, Sharma M, Kovoor A. D(2)-Dopamine receptors target regulator of G protein signaling 9-2 to detergent-resistant membrane fractions. J Neurochem. 2012;120:56-69.
Genedani S, Guidolin D, Leo G, et al. Computer-assisted image analysis of caveolin-1 involvement in the internalization process of adenosine A2A-dopamine D2 receptor heterodimers. J Mol Neurosci. 2005;26:177-184.
Iwata K, Ito K, Fukuzaki A, Inaki K, Haga T. Dynamin and rab5 regulate GRK2-dependent internalization of dopamine D2 receptors. Eur J Biochem. 1999;263:596-602.
Kim KM, Valenzano KJ, Robinson SR, Yao WD, Barak LS, Caron MG. Differential regulation of the dopamine D2 and D3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem. 2001;276:37409-37414.
Villar VAM, Jones JE, Armando I, et al. G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function of the dopamine D3 receptor. J Biol Chem. 2009;284:21425-21434.
Xiang Y, Rybin VO, Steinberg SF, Kobilka B. Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes. J Biol Chem. 2002;277:34280-34286.
Ostrom RS, Bundey RA, Insel PA. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipit rafts and caveolin signaling complexes. J Biol Chem. 2004;279:19846-19853.
Oner SS, Kaya AI, Onaran HO, Ozcan G, Uğur O. beta2-Adrenoceptor, Gs and adenylate cyclase coupling in purified detergent-resistant, low density membrane fractions. Eur J Pharmacol. 2010;630:42-52.
Rybin VO, Xu X, Lisanti MP, Steinberg SF. Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway. J Biol Chem. 2000;275:41447-41457.
Ostrom RS, Gregorian C, Drenan RM, Xiang Y, Regan JW, Insel PA. Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase. J Biol Chem. 2001;276:42063-42069.
Wright PT, Nikolaev VO, O’Hara T, et al. Caveolin-3 regulates compartmentation of cardiomyocyte beta2-adrenergic receptor-mediated cAMP signaling. J Mol Cell Cardiol. 2014;67:38-48.
Simopoulos AP. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol Neurobiol. 2011;44:203-215.
Lin P-Y, Huang S-Y, Su K-P. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry. 2010;68:140-147.
Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. Am J Psychiatry. 2006;163:1100-1102.
Lewis MD, Hibbeln JR, Johnson JE, Lin YH, Hyun DY, Loewke JD. Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. J Clin Psychiatry. 2011;72:1585-1590.
Huan M, Hamazaki K, Sun Y, et al. Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol Psychiatry. 2004;56:490-496.
Czysz AH, Rasenick MM. G-protein signaling, lipit rafts and the possible sites of action for the antidepressant effects of n-3 polyunsaturated fatty acids. CNS Neurol Disord Drug Targets. 2013;12:466-473.
Fakhoury M. Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders. Mol Neurobiol. 2016;53:2778-2786.
Erb SJ, Schappi JM, Rasenick MM. Antidepressants Accumulate in Lipit Rafts Independent of Monoamine Transporters to Modulate Redistribution of the G Protein, Gαs. J Biol Chem. 2016;291:19725-19733.
Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science. 1983;219:65-67.
Toki S, Donati RJ, Rasenick MM. Treatment of C6 glioma cells and rats with antidepressant drugs increases the detergent extraction of G(s alpha) from plasma membrane. J Neurochem. 1999;73:1114-1120.
Zhang L, Rasenick MM. Chronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipit raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. J Pharmacol Exp Ther. 2010;332:977-984.
Donati RJ, Rasenick MM. Chronic antidepressant treatment prevents accumulation of gsalpha in cholesterol-rich, cytoskeletal-associated, plasma membrane domains (lipit rafts). Neuropsychopharmacology. 2005;30:1238-1245.
Donati RJ, Rasenick MM. G protein signaling and the molecular basis of antidepressant action. Life Sci. 2003;73:1-17.
Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 1992;26:59-64.
Donati RJ, Schappi J, Czysz AH, Jackson A, Rasenick MM. Differential effects of antidepressants escitalopram versus lithium on Gs alpha membrane relocalization. BMC Neurosci. 2015;16:40.
Nothdurfter C, Tanasic S, Rammes G, Rupprecht R. Modulation of ligand-gated ion channels as a novel pharmacological principle. Pharmacopsychiatry. 2011;44:S27-34.
Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem. 2004;279:34614-34623.
Dreja K, Voldstedlund M, Vinten J, Tranum-Jensen J, Hellstrand P, Swärd K. Cholesterol depletion disrupts caveolae and differentially impairs agonist-induced arterial contraction. Arterioscler Thromb Vasc Biol. 2002;22:1267-1272.
Sommer B, Montaño LM, Carbajal V, et al. Extraction of membrane cholesterol disrupts caveolae and impairs serotonergic (5-HT2A) and histaminergic (H1) responses in bovine airway smooth muscle: role of Rho-kinase. Can J Physiol Pharmacol. 2009;87:180-195.
Yu P, Yang Z, Jones JE, et al. D1 dopamine receptor signaling involves caveolin-2 in HEK-293 cells. Kidney Int. 2004;66:2167-2180.
Yang S, Yang Y, Yu P, et al. Dopamine D1 and D5 receptors differentially regulate oxidative stress through paraoxonase 2 in kidney cells. Free Radic Res. 2015;49:397-410.
Hanson MA, Cherezov V, Griffith MT, et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure. 2008;16:897-905.
Pontier SM, Percherancier Y, Galandrin S, Breit A, Galés C, Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem. 2008;283:24659-24672.
DiPilato LM, Zhang J. The role of membrane microdomains in shaping beta2-adrenergic receptor-mediated cAMP dynamics. Mol Biosyst. 2009;5:832-837.
